CAJ | 학술논문

目的：探讨减阻剂改善实验犬冠状动脉微循环的可行性，为其进一步治疗心肌微循环障碍提供实验基础。方法：对8只实验犬行开胸手术，选择前降支区域行心肌声学造影，依次给予静脉注射腺苷，250 mg/L的减阻剂溶液，以及减阻剂+腺苷。利用函数y =A×（1-e-βt）进行拟合，计算出心肌微循环的毛细血管容积（A 值）、毛细血管血流速度（β值）及心肌血流量（A·β值）。结果：静脉注射减阻剂以后的毛细血管容积与基础状态以及静脉注射腺苷后比，差异均无统计学意义（P>0.05）。静脉注射减阻剂后与基础状态比，毛细血管血流速率[（0.57±0.10）1/s vs（0.23±0.03）1/s，P<0.01]和心肌血流量[（11.51±1.96）VI/s vs（5.15±0.86）VI/s，P<0.05]均明显增加，差异有统计学意义。但联合使用减阻剂+腺苷后毛细血管血流速率和心肌血流量与基础状态比，差异均无统计学意义（P均>0.05）。结论：减阻剂主要通过调节毛细血管血流速度来改善冠状动脉微循环血供，其独特的血流动力学疗效有望为治疗心肌微循环障碍提供新的方法。
목적：탐토감조제개선실험견관상동맥미순배적가행성，위기진일보치료심기미순배장애제공실험기출。방법：대8지실험견행개흉수술，선택전강지구역행심기성학조영，의차급여정맥주사선감，250 mg/L적감조제용액，이급감조제+선감。이용함수y =A×（1-e-βt）진행의합，계산출심기미순배적모세혈관용적（A 치）、모세혈관혈류속도（β치）급심기혈류량（A·β치）。결과：정맥주사감조제이후적모세혈관용적여기출상태이급정맥주사선감후비，차이균무통계학의의（P>0.05）。정맥주사감조제후여기출상태비，모세혈관혈류속솔[（0.57±0.10）1/s vs（0.23±0.03）1/s，P<0.01]화심기혈류량[（11.51±1.96）VI/s vs（5.15±0.86）VI/s，P<0.05]균명현증가，차이유통계학의의。단연합사용감조제+선감후모세혈관혈류속솔화심기혈류량여기출상태비，차이균무통계학의의（P균>0.05）。결론：감조제주요통과조절모세혈관혈류속도래개선관상동맥미순배혈공，기독특적혈류동역학료효유망위치료심기미순배장애제공신적방법。
Objective: To test the feasibility of drag-reducing polymers (DRP) for improving coronary microcirculation in a canine model in order to provide the experimental basis for treating myocardial microcirculation dysfunction. Methods: A total of 8 dogs received open-chest surgery and they had intravenous injections, in turn, with adenosine (ADN), DRP 250 mg/L and DRP+ADN. The function y=A × (1-e-βt) was used to calculate the myocardium capillary volume (A value), capillary velocity (β value) and myocardial blood lfow (A ? β value) by myocardial contrast echocardiography. Results: With DRP infusion, the A value in experimental canine was similar to the baseline condition,P>0.05; while theβ value and A ? β value were signiifcantly increased as (0.57 ± 0.10) 1/s vs (0.23 ± 0.03) 1/s,P<0.01 and (11.51 ± 1.96) VI/s vs (5.15 ± 0.86) VI/s,P <0.05 respectively. With combined infusion of DRP+ADN, the β value and A ? β value were similar to the baseline condition, bothP>0.05. Conclusion: DRP improved coronary microcirculation primarily by modulating the β value in experimental canine model, and hopefully, this unique hemodynamics could provide a new approach for treating myocardial microcirculation dysfunction.